How many immunotherapy trials in breast cancer translate into positive phase III trials?
Many trials fail to produce results and to translate into positive phase III trials, increasing research and drug costs. Single-center, small and non-randomized phase II trial are the most low-yield ones.
Different effects of exercise on recurrence in primary breast cancer
Postdiagnosis/pretreatment exercise may lower risk of recurrence of breast cancer, depending on subtype and menopausal status
Long-term survival data from DESTINY-Breast03 trial
With a longer follow-up of 41 months, trastuzumab-deruxtecan continues to demonstrate superior efficacy over trastuzumab-emtansine in HER2+ metastatic breast cancer
Tumor-infiltrating lymphocytes in triple-negative breast cancer
A retrospective analysis of patients treated with locoregional therapy but without adjuvant or neoadjuvant chemotherapy shows that a higher TIL abundance is associated with better survival
Chemotherapy de-escalation in HER2+ early breast cancer
A PET-based, pathological complete response-adapted strategy leads to excellent 3-year invasive disease-free survival, with a third of patients who can safely omit chemotherapy
Giredestrant in HR+/HER2- advanced breast cancer
In the phase II aceIERA trial, giredestrant was well tolerated and showed a trend toward favorabile benefit among ESR-1 mutated tumors
Effects of palbociclib and avelumab added to fulvestrant in HR+/HER2- metastatic breast cancer
Addition of palbociclib to fulvestrant did not improve progression-free survival, whereas addition of palbociclib and avelumab had positive effects: results of the PACE trial
In memoriam of Pinuccia Valagussa
With the passing of Pinuccia Valagussa, co-founder of the Michelangelo Foundation, the field of medicine loses one of the key figures of a season that set the stage of modern clinical oncology
Breast cancer treatment with PARP inhibitors, efficacy and future of research
A new review from Italian researchers summarizes evidence of efficacy of PARP inhibitors, focusing on potential new applications and the future of clinical research with these agents
Effects of neoadjuvant-adjuvant pertuzumab in HER2- positive early breast cancer
The final analysis of phase III PEONY trial confirms a positive benefit/risk ratio of neoadjuvant/adjuvant pertuzumab, trastuzumab, and docetaxel treatment in patients with HER2+ early breast cancer
